A Phase 2 interventional study of Pentadecanoic Acid and Placebo in Red Blood Cell Health, Biological Aging and Healthy Aging, sponsored by ReCellience15, Inc. Not yet recruiting at 1 site in Canada. Open to participants aged 55 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-05.
Sponsored by ReCellience15, Inc · Phase 2, Interventional, and Treatment
This Phase II randomized, double-blind, placebo-controlled, parallel-group study will evaluate the effects of pentadecanoic acid (C15:0) supplementation on red blood cell (RBC) health and predicted biological age in healthy adults aged 55 years and older. A total of 93 participants will be randomized to receive 200 mg of C15:0, 300 mg of C15:0, or placebo daily for approximately 12 weeks. The primary objective is to assess the effect of C15:0 on red blood cell distribution width (RDW-CV), a marker of RBC health, compared with placebo. Secondary outcomes include measures of inflammation, hematologic and iron metabolism markers, circulating C15:0 levels, biological age-related biomarkers, sleep quality, fatigue, energy, and health-related quality of life. Safety and tolerability will also be evaluated throughout the study.
This Phase II, randomized, double-blind, placebo-controlled, parallel-group study is designed to evaluate the effects of supplemental pentadecanoic acid (C15:0) on red blood cell (RBC) health and activity and predicted biological age in healthy older adults. The study will enroll 93 generally healthy men and women aged 55 years and older who have maintained stable dietary habits, medication and supplement use, and lifestyle practices prior to study entry.
Participants will be randomized in a 1:1:1 ratio to receive one of three interventions: C15:0 (200 mg/day), C15:0 (300 mg/day), or placebo. Study product will be administered orally as three capsules daily for a total supplementation period of approximately 84 days (12 weeks). Participants will attend a screening visit, a baseline/randomization visit, a Week 6 interim visit, and a Week 12 end-of-study visit.
The primary objective is to assess the effect of C15:0 supplementation on RBC health as measured by change from baseline in red blood cell distribution width coefficient of variation (RDW-CV) at Week 12 compared with placebo. Secondary objectives include evaluation of effects on RDW-CV at Week 6, systemic inflammation as measured by C-reactive protein (CRP), hemoglobin, hematocrit, RBC count, iron and RBC metabolism markers (reticulocytes, mean corpuscular hemoglobin concentration, serum iron, ferritin, and transferrin saturation), circulating C15:0 concentrations, and biomarkers associated with biological aging.
Biological aging outcomes include Phenotypic Age Acceleration (PhenoAgeAccel) score and the specific biological age-related biomarkers (glucose, mean corpuscular volume, white blood cell count and differential, creatinine, alkaline phosphatase, albumin, and lymphocyte percentage). Additional assessments will evaluate sleep quality, fatigue, energy, and health-related quality of life using the PROMIS Sleep Disturbance 8a, PROMIS Fatigue 8a, Energy Visual Analog Scale, and RAND-36 Health Survey, respectively.
Exploratory analyses will assess biomarkers of biological aging and oxidative stress, including interleukin-6 (IL-6) and malondialdehyde (MDA). Safety evaluations will include adverse events, vital signs, anthropometric measurements, and clinical laboratory assessments throughout the study.
The study aims to determine whether C15:0 supplementation can improve markers of RBC health and function while positively influencing biological aging-related pathways in healthy older adults.
3,536 studies on the registry are indexed under Inflammation; 642 are open to participants now.
This study's planned enrollment of 93 is above the median of 50 across 2,577 interventional studies indexed under Inflammation.
Browse Inflammation studies →This is the only study on the registry with ReCellience15, Inc as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The other ingredients in a medicine besides the active drug, such as fillers, colours or preservatives.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colours or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive 200 mg/day pentadecanoic acid (C15:0) administered as three capsules daily (2 active capsules and 1 placebo capsule) for approximately 12 weeks.
Dietary Supplement: Pentadecanoic Acid
Participants receive 300 mg/day pentadecanoic acid (C15:0) administered as three active capsules daily for approximately 12 weeks.
Dietary Supplement: Pentadecanoic Acid
Participants receive three placebo capsules daily for approximately 12 weeks. Placebo capsules are matched to the active study product in appearance and packaging.
Other: Placebo
Pentadecanoic acid is administered orally as capsules once daily with the participant's first meal for approximately 12 weeks (84 ± 2 days). Participants receive one daily dose consisting of three capsules. The 200 mg/day group receives two active capsules and one placebo capsule, while the 300 mg/day group receives three active capsules. Participants take their first dose in-clinic on Day 1 and continue daily dosing at home from Day 2 through the day before the end-of-study visit.
Also known as: C15:0
Placebo is administered orally as three matching placebo capsules once daily with the participant's first meal for approximately 12 weeks (84 ± 2 days). Placebo capsules are manufactured to match the active study product in physical appearance and packaging to maintain blinding.
To assess the effect of the test product (TP) at two dose levels on red blood cell (RBC) health, as measured by red blood cell distribution width (RDW), compared to placebo
Change from baseline in RDW-CV (%) at Week 12, adjusted for baseline RDW, comparing each active dose (200 mg/day and 300 mg/day) to placebo
Time frame: Change from baseline at Week 12
To evaluate early changes in RBC health at two dose levels, as measured by RDW, compared to placebo
Change from baseline in RDW-CV (%) at Week 6, adjusted for baseline RDW, comparing each active dose to placebo
Time frame: Change from baseline at Week 6
To assess the effect of the TP at two dose levels on systemic inflammation, as measured by C-reactive protein (CRP), compared to placebo
Change from baseline in CRP (mg/L) at Week 6 and Week 12 comparing each active dose to placebo
Time frame: Change from baseline at Week 6 and Week 12
To evaluate the effect of the TP at two dose levels on hemoglobin levels compared to placebo
Change from baseline in hemoglobin (g/dL) at Week 6 and Week 12 comparing each active dose to placebo
Time frame: Change from baseline at Week 6 and Week 12
To evaluate the effect of the TP at two dose levels on hematocrit compared to placebo
Change from baseline in hematocrit (%) at Week 6 and Week 12 comparing each active dose to placebo
Time frame: Change from baseline at Week 6 and Week 12
To evaluate the effect of the TP at two dose levels on RBC count compared to placebo
Change from baseline in RBC count (10¹²/L) at Week 6 and Week 12 comparing each active dose to placebo
Time frame: Change from baseline at Week 6 and Week 12
To evaluate the effect of the TP at two dose levels on circulating C15:0 fatty acid concentrations compared to placebo
Change from baseline in plasma C15:0 levels and erythrocyte membrane fatty acid composition at Week 12 comparing each active dose to placebo
Time frame: Change from baseline at Week 12
To evaluate the effect of the TP at two dose levels on RBC metabolism markers compared to placebo
Change from baseline in reticulocytes at Week 12 comparing each active dose to placebo
Time frame: Change from baseline at Week 12
To evaluate the effect of the TP at two dose levels on RBC metabolism markers compared to placebo
Change from baseline in mean corpuscular hemoglobin concentration (MCHC) at Week 12 comparing each active dose to placebo
Time frame: Change from baseline at Week 12
To evaluate the effect of the TP at two dose levels on markers of iron status compared to placebo
Change from baseline in serum iron at Week 12 comparing each active dose to placebo
Time frame: Change from baseline at Week 12
To evaluate the effect of the TP at two dose levels on markers of iron status compared to placebo
Change from baseline in ferritin at Week 12 comparing each active dose to placebo
Time frame: Change from baseline at Week 12
To evaluate the effect of the TP at two dose levels on markers of iron status compared to placebo
Change from baseline in transferrin saturation at Week 12 comparing each active dose to placebo
Time frame: Change from baseline at Week 12
To evaluate the effect of the TP at two dose levels on biological age-related biomarkers compared to placebo
Change from baseline in glucose at Week 12 comparing each active dose to placebo
Time frame: Change from baseline at Week 12
To evaluate the effect of the TP at two dose levels on biological aging
Change from baseline in Phenotypic Age Acceleration (PhenoAgeAccel) at Week 12 comparing each active dose to placebo
Time frame: Change from baseline at Week 12
To evaluate the effect of the TP at two dose levels on biological age-related biomarkers compared to placebo
Change from baseline in mean corpuscular volume (MCV) at Week 12 comparing each active dose to placebo
Time frame: Change from baseline at Week 12
To evaluate the effect of the TP at two dose levels on biological age-related biomarkers compared to placebo
Change from baseline in white blood cell (WBC) count + differential at Week 12 comparing each active dose to placebo
Time frame: Change from baseline at Week 12
To evaluate the effect of the TP at two dose levels on biological age-related biomarkers compared to placebo
Change from baseline in creatinine at Week 12 comparing each active dose to placebo
Time frame: Change from baseline at Week 12
To evaluate the effect of the TP at two dose levels on biological age-related biomarkers compared to placebo
Change from baseline in alkaline phosphatase (ALP) at Week 12 comparing each active dose to placebo
Time frame: Change from baseline at Week 12
To evaluate the effect of the TP at two dose levels on biological age-related biomarkers compared to placebo
Change from baseline in albumin at Week 12 comparing each active dose to placebo
Time frame: Change from baseline at Week 12
To evaluate the effect of the TP at two dose levels on biological age-related biomarkers compared to placebo
Change from baseline in lymphocyte % at Week 12 comparing each active dose to placebo
Time frame: Change from baseline at Week 12
To evaluate the effect of the TP at two dose levels on sleep quality compared to placebo
Change from baseline in PROMIS Sleep Disturbance 8a at Week 12 comparing each active dose to placebo
Time frame: Change from baseline at Week 12
To evaluate the effect of the TP at two dose levels on energy compared to placebo
Change from baseline in PROMIS Fatigue 8a at Week 12 comparing each active dose to placebo
Time frame: Change from baseline at Week 12
To evaluate the effect of the TP at two dose levels on energy compared to placebo
Change from baseline in Energy Visual Analog Scale at Week 12 comparing each active dose to placebo
Time frame: Change from baseline at Week 12
To evaluate the effect of the TP at two dose levels on health-related quality of life compared to placebo
Change from baseline in RAND-36 at Week 12 comparing each active dose to placebo
Time frame: Change from baseline at Week 12
To assess heart rate for safety
Heart rate (bpm) is assessed for safety of the TP
Time frame: From baseline to Week 12
To assess blood pressure for safety
Blood pressure (mmHg) assessed for safety of the TP
Time frame: From baseline to Week 12
To assess weight for safety
Weight (kg) is assessed for safety of the TP
Time frame: From baseline to Week 12
To assess body mass index for safety
Body Mass Index (kg/m2) is assessed for safety of the TP
Time frame: From baseline to Week 12
To assess mean corpuscular volume in blood samples for safety
Fasting blood samples will be collected to assess the safety and tolerability of the investigational product through evaluation of hematology parameter, mean corpuscular volume.
Time frame: From baseline to Week 12
To assess mean corpuscular hemoglobin in blood samples for safety
Fasting blood samples will be collected to assess the safety and tolerability of the investigational product through evaluation of hematology parameter, mean corpuscular hemoglobin.
Time frame: From baseline to Week 12
To assess mean corpuscular hemoglobin concentration in blood samples for safety
Fasting blood samples will be collected to assess the safety and tolerability of the investigational product through evaluation of hematology parameter, mean corpuscular hemoglobin concentration.
Time frame: From baseline to Week 12
To assess white blood cell count and differential in blood samples for safety
Fasting blood samples will be collected to assess the safety and tolerability of the investigational product through evaluation of hematology parameter, white blood cell count and differential.
Time frame: From baseline to Week 12
To assess platelet count in blood samples for safety
Fasting blood samples will be collected to assess the safety and tolerability of the investigational product through evaluation of hematology parameter, platelet count.
Time frame: From baseline to Week 12
To assess mean platelet volume in blood samples for safety
Fasting blood samples will be collected to assess the safety and tolerability of the investigational product through evaluation of hematology parameter, mean platelet volume.
Time frame: From baseline to Week 12
To assess urea in blood samples for safety
Fasting blood samples will be collected to assess the safety and tolerability of the investigational product through evaluation of clinical chemistry parameter, urea.
Time frame: From baseline to Week 12
To assess creatinine in blood samples for safety
Fasting blood samples will be collected to assess the safety and tolerability of the investigational product through evaluation of clinical chemistry parameter, creatinine.
Time frame: From baseline to Week 12
To assess total bilirubin in blood samples for safety
Fasting blood samples will be collected to assess the safety and tolerability of the investigational product through evaluation of clinical chemistry parameter, total bilirubin.
Time frame: From baseline to Week 12
To assess alkaline phosphatase in blood samples for safety
Fasting blood samples will be collected to assess the safety and tolerability of the investigational product through evaluation of clinical chemistry parameter, alkaline phosphatase.
Time frame: From baseline to Week 12
To assess aspartate aminotransferase in blood samples for safety
Fasting blood samples will be collected to assess the safety and tolerability of the investigational product through evaluation of clinical chemistry parameter, aspartate aminotransferase.
Time frame: From baseline to Week 12
To assess alanine aminotransferase in blood samples for safety
Fasting blood samples will be collected to assess the safety and tolerability of the investigational product through evaluation of clinical chemistry parameter, alanine aminotransferase.
Time frame: From baseline to Week 12
To assess fasting serum glucose in blood samples for safety
Fasting blood samples will be collected to assess the safety and tolerability of the investigational product through evaluation of clinical chemistry parameter, fasting serum glucose.
Time frame: From baseline to Week 12
To assess albumin in blood samples for safety
Fasting blood samples will be collected to assess the safety and tolerability of the investigational product through evaluation of clinical chemistry parameter, albumin.
Time frame: From baseline to Week 12
To assess globulin in blood samples for safety
Fasting blood samples will be collected to assess the safety and tolerability of the investigational product through evaluation of clinical chemistry parameter, globulin.
Time frame: From baseline to Week 12
To assess total protein in blood samples for safety
Fasting blood samples will be collected to assess the safety and tolerability of the investigational product through evaluation of clinical chemistry parameter, total protein.
Time frame: From baseline to Week 12
To assess sodium in blood samples for safety
Fasting blood samples will be collected to assess the safety and tolerability of the investigational product through evaluation of clinical chemistry parameter, sodium.
Time frame: From baseline to Week 12
To assess potassium in blood samples for safety
Fasting blood samples will be collected to assess the safety and tolerability of the investigational product through evaluation of clinical chemistry parameter, potassium.
Time frame: From baseline to Week 12
To assess estimated glomerular filtration rate in blood samples for safety
Fasting blood samples will be collected to assess the safety and tolerability of the investigational product through evaluation of clinical chemistry parameter, estimated glomerular filtration rate.
Time frame: From baseline to Week 12
To assess chloride in blood samples for safety
Fasting blood samples will be collected to assess the safety and tolerability of the investigational product through evaluation of clinical chemistry parameter, chloride.
Time frame: From baseline to Week 12
To assess reports of adverse events for safety
Reports of adverse events will be evaluated to assess the safety of the TP
Time frame: From baseline to Week 12
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Jan 2027; primary completion for Jun 2027, 5 months later.
Of 36 industry-sponsored phase 2 interventional studies under Inflammation, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's planned 5 months is below that.
Counting every sponsor, half of 149 studies reached it within 29 months; a quarter within 16 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.